Easton Pharmaceuticals, Inc. (EAPH)

White-LogoA specialty pharmaceutical company, Easton Pharmaceuticals, Inc designs, develops, and markets topical health care products. These premium products provide various therapeutic benefits using the company’s proprietary gel formulation to deliver transdermal effects. In 2013, the Toronto, Canada-based company announced that it has also made initiatives to enter the medical marijuana sector.

The current products of Easton Pharmaceuticals cater to a variety of health issues. It has an anti-wrinkle cream called Skin Renou HA, an arthritis- and body pain-reliever called Kenestrin Gel, a motion sickness gel called Nauseasol, and a female sexual enhancement gel called Viorra. All of these are applied through the unique transdermal delivery system.

Aside from these, two products in the company’s pipeline are XILIVE, an early-stage cancer drug, and Femlife, a transdermal drug to treat Female Sexual Arousal Disorder (FSAD).

In June 2013, Easton Pharmaceuticals announced its intent to open medical cannabis clinics in the US and Canada. More recently, in June 2014, the company has started discussing investment proposals, including one to a medical marijuana dispensary in Michigan.

The company has also made an investment in AMFIL Technologies, the manufacturer of the mPact-GROzone Antimicrobial System. This system utilizes ozone technologies to minimize pathogens and pests in marijuana growing facilities.

Founded in 1997 as LAM Pharmaceutical Corp, Easton Pharmaceuticals changed to its current name in 2010. It is currently being traded in the OTC markets under the symbol EAPH, with a market cap of USD 1.26 M.

Among the company’s key executives are Carla Pepe, CEO and President; John Adams, CFO; Kent A. Deuters, COO; Dr. Peter J. Rothbart, Treasurer; Dr. Daniel Bagi, Senior Executive Physician Consultant; and Dr. Lilla Albert, Chief Marketing and Technology Officer.


Yahoo! Finance: EAPH News

Latest Financial News for EAPH

Easton Pharmaceuticals Turns to Profit in Q1, Provides Business Update

TORONTO, June 13, 2019 (GLOBE NEWSWIRE) -- via NetworkWire -- Easton Pharmaceuticals Inc. (OTC: EAPH) (“Easton” or “the Company”) announces it has filed its quarterly report for the three months ended March 31, 2019, and provides several key updates on its business initiatives. In the first quarter of 2019, Easton Pharmaceuticals recorded revenues of $612,689 and turned from a loss to post net income of $7,878. Revenues were generated from the Company’s contract with a prominent developer to frame 150 new homes in Whitby, Ontario, Canada, under its newly created real estate development division.

Easton Announces That it Is Moving its Corporate Office After the Purchase of its Food Processing Company Specializing in Baked Goods and the Launch of its New Website

TORONTO, ON / ACCESSWIRE / April 30, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) executive management is pleased to announce the move of its corporate head office from Elm Street, Toronto, Ontario to Brockhouse Road, Toronto, Ontario. Easton confirms that with the acquisition of Supreme Sweets Inc. the management will be joining the Easton team at the Brockhouse Road facility and adding the extensive product line up to its growing product group within the Company's Food and Beverage operation. This move will allow Easton to oversee their Food & Beverage, Real Estate and Gaming all within the same physical premises.

Easton Closes Purchase of Food Processing Company Specializing in Baked Goods with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market

TORONTO, ON / ACCESSWIRE / April 24, 2019 / Easton Pharmaceuticals, Inc. (the "Company" or "Easton") (OTC PINK: EAPH) is pleased to announce that it has now officially closed on its acquisition of a food processing company based in Toronto, Canada. Easton has completed its acquisition of Supreme Sweets Inc. and 2498411 Ontario Inc. (collectively the "Acquiree"), which includes all the tangible and intangible assets of the company such as equipment, intellectual property (patents, trade secrets, formulas, etc.) and client lists of both Supreme Sweets Inc. and 2498411 Ontario Inc. The purchase was completed with a combination of cash and Easton stock.

Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery

TORONTO, ON / ACCESSWIRE / April 12, 2019 / Easton Pharmaceuticals, Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier this week that its legal counsel believed that all documents would be completed this week with signatures and exchange of documents. Easton is acquiring a revenue generating commercial bakery and food preparation company in Toronto, Ontario, Canada.

Easton Provides Update on the Closing of its Agreement To Acquire Commercial Bakery with Projected Revenues Over $20,000,000 per Year and Positioned to Enter the Cannabis Edibles Market

TORONTO, ON / ACCESSWIRE / April 8, 2019 / Easton Pharmaceuticals Inc. (OTC PINK: EAPH) provides update on the closing of its agreement to acquire a commercial bakery with existing revenues and projected to reach over $20,000,000 within 12 months. Easton announced earlier in March that it had signed a Definitive Agreement to acquire a commercial bakery and food preparation company with existing revenues and projected revenues in excess of $20,000,000 over the next 12 months. Easton's legal counsel believes that all documents will be completed this week with signatures and exchange of documents.